Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:16969035rdf:typepubmed:Citationlld:pubmed
pubmed-article:16969035lifeskim:mentionsumls-concept:C0087111lld:lifeskim
pubmed-article:16969035lifeskim:mentionsumls-concept:C0877550lld:lifeskim
pubmed-article:16969035lifeskim:mentionsumls-concept:C0024623lld:lifeskim
pubmed-article:16969035lifeskim:mentionsumls-concept:C0008838lld:lifeskim
pubmed-article:16969035lifeskim:mentionsumls-concept:C1521996lld:lifeskim
pubmed-article:16969035lifeskim:mentionsumls-concept:C1533148lld:lifeskim
pubmed-article:16969035lifeskim:mentionsumls-concept:C1704419lld:lifeskim
pubmed-article:16969035lifeskim:mentionsumls-concept:C0205179lld:lifeskim
pubmed-article:16969035lifeskim:mentionsumls-concept:C1172402lld:lifeskim
pubmed-article:16969035lifeskim:mentionsumls-concept:C2828372lld:lifeskim
pubmed-article:16969035pubmed:issue9lld:pubmed
pubmed-article:16969035pubmed:dateCreated2006-9-13lld:pubmed
pubmed-article:16969035pubmed:abstractTextWe encountered a resected case of advanced gastric cancer after successful chemotherapy. The patient remained alive in good condition without any signs of recurrence at 2 years and 8 months after surgery. The 40-year-old woman initially complained of low abdominal pain, which was diagnosed as gastric cancer with metastasis of ovaries and carcinomatous ascites. We administered TS-1 (100 mg/body/day) for 3 weeks followed by 2-week rest and CDDP (60 mg/body) on the 8th day of one cycle. After 3 cycles of treatment, carcinomatous ascites disappeared and the ovarian lesion was reduced. The patient underwent total gastrectomy, ileocecal resection, cholecystectomy and radical hysterectomy. The antitumor efficacy of the treatment was histologically Grade 2. We administered 17 cycles of TS-1 treatment, and the patient is alive in good condition at this writing. This shows that TS-1 and CDDP may have potent therapeutic efficacy in advanced gastric cancer patients. For the future, the safety and efficacious administration of TS-1 and CDDP should be examined further.lld:pubmed
pubmed-article:16969035pubmed:languagejpnlld:pubmed
pubmed-article:16969035pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16969035pubmed:citationSubsetIMlld:pubmed
pubmed-article:16969035pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16969035pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16969035pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16969035pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16969035pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16969035pubmed:statusMEDLINElld:pubmed
pubmed-article:16969035pubmed:monthSeplld:pubmed
pubmed-article:16969035pubmed:issn0385-0684lld:pubmed
pubmed-article:16969035pubmed:authorpubmed-author:ToshimitsuHir...lld:pubmed
pubmed-article:16969035pubmed:authorpubmed-author:ShimizuRyoich...lld:pubmed
pubmed-article:16969035pubmed:authorpubmed-author:MatobaKatsuhi...lld:pubmed
pubmed-article:16969035pubmed:authorpubmed-author:OzasaHiroakiHlld:pubmed
pubmed-article:16969035pubmed:issnTypePrintlld:pubmed
pubmed-article:16969035pubmed:volume33lld:pubmed
pubmed-article:16969035pubmed:ownerNLMlld:pubmed
pubmed-article:16969035pubmed:authorsCompleteYlld:pubmed
pubmed-article:16969035pubmed:pagination1329-32lld:pubmed
pubmed-article:16969035pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:16969035pubmed:meshHeadingpubmed-meshheading:16969035...lld:pubmed
pubmed-article:16969035pubmed:meshHeadingpubmed-meshheading:16969035...lld:pubmed
pubmed-article:16969035pubmed:meshHeadingpubmed-meshheading:16969035...lld:pubmed
pubmed-article:16969035pubmed:meshHeadingpubmed-meshheading:16969035...lld:pubmed
pubmed-article:16969035pubmed:meshHeadingpubmed-meshheading:16969035...lld:pubmed
pubmed-article:16969035pubmed:meshHeadingpubmed-meshheading:16969035...lld:pubmed
pubmed-article:16969035pubmed:meshHeadingpubmed-meshheading:16969035...lld:pubmed
pubmed-article:16969035pubmed:meshHeadingpubmed-meshheading:16969035...lld:pubmed
pubmed-article:16969035pubmed:meshHeadingpubmed-meshheading:16969035...lld:pubmed
pubmed-article:16969035pubmed:meshHeadingpubmed-meshheading:16969035...lld:pubmed
pubmed-article:16969035pubmed:meshHeadingpubmed-meshheading:16969035...lld:pubmed
pubmed-article:16969035pubmed:meshHeadingpubmed-meshheading:16969035...lld:pubmed
pubmed-article:16969035pubmed:meshHeadingpubmed-meshheading:16969035...lld:pubmed
pubmed-article:16969035pubmed:meshHeadingpubmed-meshheading:16969035...lld:pubmed
pubmed-article:16969035pubmed:meshHeadingpubmed-meshheading:16969035...lld:pubmed
pubmed-article:16969035pubmed:meshHeadingpubmed-meshheading:16969035...lld:pubmed
pubmed-article:16969035pubmed:meshHeadingpubmed-meshheading:16969035...lld:pubmed
pubmed-article:16969035pubmed:meshHeadingpubmed-meshheading:16969035...lld:pubmed
pubmed-article:16969035pubmed:year2006lld:pubmed
pubmed-article:16969035pubmed:articleTitle[A resected case of effective treatment with TS-1 and CDDP for advanced gastric cancer with carcinomatous ascites].lld:pubmed
pubmed-article:16969035pubmed:affiliationDept. of Surgery, Ogori Daiichi General Hospital.lld:pubmed
pubmed-article:16969035pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:16969035pubmed:publicationTypeEnglish Abstractlld:pubmed
pubmed-article:16969035pubmed:publicationTypeCase Reportslld:pubmed